Has my stock been accused of fraud?Join over 160k users who know.

Ticker Price Change($) Change(%) Shares Volume Prev Close Open Gain($) Gain(%)
Ticker Status Jurisdiction Filing Date CP Start CP End CP Loss Deadline
Ticker Case Name Status CP Start CP End Deadline Settlement Amt
Ticker Name Date Analyst Firm Up/Down Target ($) Rating Change Rating Current

News

Emergent BioSolutions Narrows FY2025 Sales Guidance from $750.00M-$850.00M to $765.00M-$835.00M vs $800.00M Est

Author: Benzinga Newsdesk | August 06, 2025 04:17pm
Emergent BioSolutions (NYSE:EBS) narrows FY2025 sales outlook from $750.00 million-$850.00 million to $765.00 million-$835.00 million vs $800.00 million estimate.

Posted In: EBS

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION

CORE Finalist